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Poster Session II S313and 96 standard. ForHLA, there were 45HLA 10/10, 14HLA 9/10,
1 HLA 8/10 and for UCB 14 HLA 4/6 and 3 HLA 5/6. After a me-
dian follow-up of 25 months (0.2- 234), the median OS was 78
months (51–133) for transplanted patients with SD (3years OS:
68%), it was 33 months (27–47) for transplanted patients with UD
(3years OS:44%), 21 months (15–37) for not transplanted patients
with available SD or UD (3years OS:34%) and it was 31 months
(23-221) for patients with ND (3years OS:45%). Median EFS for
the same groups was 38 months (23–133), 24 months (17–36), 15
months (11-24) and 23 months (14–48) respectively. In multivariate
analysis, 3 significant factors affected OS: disease status (\CR) HR
5 2.8 [1.5-5.3] p\0.001; long interval diagnosis-registration HR5
2 [1.2-3.6] p 5 0.001 and conditioning (standard) HR 5 0.27 [0.1-
0.8] p5 0.02. The interval diagnosis-registration appeared as major
factor affecting survival in UD allo-HSCT settings.
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LONG TERM OUTCOMES OF ALLOGENEIC TRANSPLANT USING NON-RA-
DIATION BASED PREPARATIVE REGIMENS FOR ACUTE LYMPHOBLASTIC
LEUKEMIA
Al-Khabori, M., Al-Rawas, A., Al-Kindi, S., Al-Huneini, M., Al-
Farsi, K., Al Mandhari, I., Al-Mahrizi, R., Al-Zadjali, S.,
Dennison, D. Sultan Qaboos University Hospital, Al-Khoud, Muscat,
Oman
The role of total body irradiation (TBI) in the preparative regimen
before allogeneic stem cell transplantation has been debated. It is as-
sociated with higher rates of toxicity. Herein, we report the long
term outcomes of 26 consecutive pediatric and adult patients trans-
planted for acute lymphoblastic leukemia (ALL) in our center with
non-TBI based preparative regimens from February 1996 to June
2010. All records were retrospectively reviewed. The median age
was 15 years (y); range 4-31, with 18 males and 8 females. Thirteen
were in first complete remission (CR1), 12 in CR2 and 1 patient with
progressive disease at the time of transplant. All preparative regimens
comprised of busulfan combined withmelphalan in 3, cyclophospha-
mide in 14 and fludarabine in 9 patients. The source of the graft was
bone marrow in 14 and peripherally collected stem cells in 12 pa-
tients. The median follow up was 54 and 83 months (mos) for all
and alive patients respectively. During the study follow up, there
were 9 relapses and 9 deaths (8 relapse related). The median overall
survival (OS) was 18 mos (95% confidence interval [CI]: 4-21) with
5-y probability of 63% (95% CI: 40-79%). The median disease free
survival (DFS) was 10.4 mos (95% CI: 5-19) with 5-y probability of
61% (95% CI: 39-78%). The 5-y cumulative incidence of relapse
was 39% (95% CI: 19-58%) for all group, 13% (95% CI: 0.5-
44%) for patients aged upto 12 y and 53% (95%CI: 25-75%) for pa-
tients over 12 y of age. Thirty-three percent of patients (95%CI: 13-
54%) had acute graft versus host disease (aGvHD) grade 2 while
none had grade 3-4. Nineteen percent (95% CI: 1-37%) had exten-
sive chronic GvHD while only one had limited cGvHD. In the mul-
tivariable Cox model of OS using age (continuous variable) and
disease status at transplant (CR2 versus CR1), both factors were sta-
tistically significant. The hazard ratio (HR) of age and disease status
were 1.18 (95% CI: 1.03-1.35) and 10.90 (95% CI: 1.05-112.30) re-
spectively. In conclusion, non-TBI based preparative regimen in
children with ALL is a reasonable alternative with excellent results.
The age and disease status at transplantation have major impact on
survival of those patients. Further larger study is needed to validate
these results.
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HIGH RATES OF NON-RELAPSE MORTALITY AND GRAFT-VERSUS-HOST
DISEASE IN PATIENT UNDERGOING ALLOGENEIC STEM CELL TRANS-
PLANTATION (ASCT) FOLLOWING NON-MYELOABLATIVE (NMA) CONDI-
TIONING WITH TLI/ATG
Kanate, A.S.1, Chaudhary, L.2, Cumpston, A.3, Leadmon, S.1,
Bunner, P.1, Bulian, D.1, Gibson, L.1, Tse, W.1, Abraham, J.1,
Remick, S.1, Craig, M.1, Hamadani, M.1 1West Virginia University,
Morgantown, WV; 2West Virginia University, Morgantown, WV;
3West Virginia University, Morgantown, WV
NMA conditioning with TLI/ATG (TA) has shown remarkably
low rates of acute graft-versus-host disease (GVHD) and non-re-
lapse mortality (NRM). Randomized comparisons of TA withmore intense conditioning regimens have not been performed. We
report here a retrospective comparison of transplant outcome fol-
lowing NMA with TA or reduced ‘‘toxicity’’ conditioning with flu-
darabine, busulfan and ATG (FBA), in cohort of patients deemed
not suitable for conventional myeloablative conditioning regimens.
The study group consists of 48 consecutive patients who under-
went ASCT after conditioning with FBA (n 5 37) or TA (n 5 11)
because of advanced age or presence of co-morbidities. FBA regimen
consisted of fludarabine 40mg/m2/day and busulfan 130mg/m2/day
intravenously x4 doses starting day -6 and ATG 2mg/kg/day for 3
days, starting day -3. TA group received ATG 1.5mg/kg/day for 5
days and TLI dose of 800 cGy starting day -11.
Baseline characteristics are in table 1.
Table 1. Patient Characteristics
Variables FBA (n537) TA (n511) p - valueSex : n (%) 0.74
Men 21 (57) 7 (64)
Women 16 (43) 4 (36)
Age: median (range) 53 (17-65) 58 (38-70) 0.20
Diagnosis: n (%) 0.01
Acute Leukemia/MDS 24 (65) 2 (18)
Non-Hodgkin Lymphoma 8 (22) 8 (73)
Chronic Leukemia 3 (8) 1 (9)
Plasma Cell Disorder 2 (5) 0 (0)
Remission Status: n (%) 0.09
Chemo-sensitive 28 (76) 11 (100)
Chemo-refractory 9 (24) 0 (0)
Risk group: n (%) 0.25
Standard risk 12 (32) 1 (9)
High risk 25 (68) 10 (91)
Prior autologous transplant: n
(%)5 (13) 1 (9) 1.00Donor type: n (%) 0.26
Sibling 9 (24) 5 (45)
Unrelated 28 (76) 6 (55)
HLA mismatch: n (%) 7 (19) 1 (9) 0.66
CD 34+ dose: median (range) [x
10*6/Kg body weight]7.2 (4-12.8) 5.1 (2.6-9) 0.03The median follow up of surviving patients is 1 year. The rate of
grade II-IV acute GVHD in the FBA and TA groups was 45.9%(n
5 17) and 36.3% (n 5 4) respectively (p 5 0.73). Rate of Grade
III-IV acute GVHD in the two groups was 8% (n 5 3) and 36.3%
(n5 4) respectively (p5 0.02). The rate of chronicGVHD in similar
order was 37.8% and 36.8% (p5 1.0). Post transplant rates of proven
bacterial, fungal and BK virus infections and CMV reactivation were
similar between the two groups (p. 0.05). The cumulative incidence
of disease relapse at 2years for FBA and TA groups was 46% and
10% respectively (p 5 0.1). non-relapse mortality (NRM) for the
FBA and TA cohorts at day 100 (2% vs.0%) and 2 years (31%
vs.30%) was not significantly different (p 5 0.3). Compared to
FBA group, TA groups showed trends towards improved 2 year
OS (40% vs.60%; p 5 0.07) and significantly better 2year progres-
sion free survival (36% vs.60%; p 5 0.036).
Acknowledging the limitation of our study (including small sam-
ple size, retrospective nature, higher proportion of chemosensitive/
low-risk patients in TA group), it is worth noting that NRM rates
with TA are surprisingly identical to an ablative FBA conditioning.
Rates of grade III-IV acute GVHD are also significanlty higher de-
spite small patient numbers. The difference is PFS is likely due to
low relapse rates in a standard-risk patient population. Our data
highlight the need for prospective studies to define optimal
conditioning regimens.
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PREDICTIVE FACTORS FOR HOSPITALIZATION AFTER OUTPATIENT RE-
DUCED-INTENSITY CONDITIONING (RIC) ALLOGENEIC HEMATOPOIETIC
PROGENITOR CELL TRANSPLANTATION (AHPCT)
Shadman, M., Rybicki, L., Kalaycio, M., Copelan, E., Andresen, S.,
Pohlman, B., Dean, R., Duong, H., Bolwell, B., Sobecks, R. Cleveland
Clinic, Cleveland, OH
Table 1. HCT data.
OBu IVBu Global p
N 23 43 66
Age 23 (21-62) 39 (8-71) 45 ( 8-71) 0.08
Graft Failure 1 (4,3%) 3 (7%) 4 (6%) 0.56
Neutrophil recovery (days) 17 (8-42) 17 (0-61) 17 (0-61) 0.95
Platelet recovery (days) 22 (11-77) 20 (0-116) 21 (0-116) 0.04
GVHD Acute 6 (26%) 9 (21%) 23 % 0.42
GVHD Chronic 4 (17%) 13 (30%) 26% 0.20
EVOH 5 (21%) 3 (7%) 8 (12 %) 0.08
Hepatotoxicity 9 (47%) 6 (27%) 15 (23%) 0.20
Relapse 3 (13%) 12 (28%) 15 (23%) 0.20
Death 14 ( 60%) 21 (48%) 35 (53%) 0.44
Progression 3 (13%) 9 (21%) 12 (18%) 0.37
GVHD 4 (17%) 4 (9%) 8 (12%) 0.37
Infection 4 (17%) 4 (9%) 9 (14%) 0.37
EVOH 2 (8%) 1 (2%) 3 (4%) 0.37
Univariate Chi-Square Test.
S314 Poster Session IIAlthough RIC AHPCT can be performed as an outpatient, many
pts who receive this therapy still are later hospitalized. An assessment
of predictive factors prior to transplant would be useful to help de-
velop strategies to reduce hospitalizations after outpatient RIC
AHPCT as well as to counsel pts further regarding post-transplant
risk.We retrospectively evaluated 132 consecutive adult pts with he-
matologic diseases who received RIC AHPCT at our institution
from 1/2000-12/2009. Pts received fludarabine and either 200 cGy
(N5 45) or 400 cGy (N5 87) TBI. GVHD prophylaxis: mycophe-
nolate and either cyclosporine for those with related donors (N5 79)
or tacrolimus for those with unrelated donors (N5 53). Median age
was 57 years (range, 18-70) and 78 were males. Diagnoses included
73 myeloid and 55 lymphoid malignancies and 4 hematologic dis-
eases. 92 had no HLA disparate donor, 12 had an HLA disparity at
HLA-A, B, C or DRB1 (major), and 28 had an HLA disparity at
HLA-DQ or DP (minor). CIBMTR comorbidity index (CI): 51
low, 43 intermediate and 38 high risk pts. 120 (90%) were hospital-
ized post transplant at a median of 14 days (range, day 0 to +475) and
the most common reasons were: 72 fevers, 46 infections and 19 acute
GVHD. Risk factors for hospitalization were assessed by Cox pro-
portional hazards analysis. Variables included gender, age, CI, no.
prior chemotherapies, prior radiation, diagnosis, TBI dose, donor
relationship,HLAdisparities, TNC/CD34+ doses and time of trans-
plant relative to the 1st one on 1/10/00. From the univariable anal-
ysis the no. of prior chemotherapies, TBI dose, unrelated donor
and HLA disparity were associated with an increased risk for hospi-
talization, while a larger TNC dose was associated with a lower risk.
In multivariable analysis 2 variables remained prognostic: 400 cGy
TBI (p 5 0.026) and HLA disparity [minor/none; p\ 0.001; ma-
jor/none; p 5 0.07]. Although the majority of pts received 400
cGy TBI, we previously did not find a difference in time to neutro-
phil engraftment compared to those receiving 200 cGyTBI (Sobecks
et al. BMT 2008;42:715-22). We conclude that HLA disparities and
400 cGyTBImay delay immune reconstitution resulting in more in-
fections that require hospitalization after RIC AHPCT. Future
strategies to enhance immune reconstitution after this approach
are warranted and if effective may have important implications re-
garding reductions in expenses and healthcare resources associated
with inpatient hospitalization.442
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION USING INTRA-
VENOUS BUSULFAN IN MYELOABLATIVE AND REDUCED-INTENSITY
CONDITIONING REGIMEN IN ACUTE LEUKEMIA PATIENTS. A COMPARI-
SON ANALYSIS WITH ORAL BUSULFAN
Sampol, A., Gutierrez, A., Ballester, C., Gual, C., Canaro, M., Novo, A.,
Galmes, A., Morey, M., Duran, M.A., Lo Rizzo, L., Besalduch, J. Hospi-
tal Universitario Son Dureta, Palma De Mallorca, Balearic Island, Spain
Introduction: Recently oral Busulfan (OBu) has been replaced by
intravenous Bu (IVBu) in allogeneic stem cell transplantation
(HCT) conditioning regimens in acute leukaemia (AL) due more
predictable pharmacokinetic and lower toxicity.
Patients andMethods:We present results from a single centre, ret-
rospective study, using IVBu vs OBu plus Fludarabine (Flu) or Cy-
clofosfamide (Cy) as a reduced-intensity (RIC) and myeloablative
conditioning regimen in AL patients.
We analyzed 66 patients, from 2000 to 2010, with a median age 45
(8-71) years, 27 patients received HCTwith RIC, Flu 150 mg/m2 in
5 days and IVBu 8,2 mg/m2 or OBu 10 mg/kg in 3 days and 39 pa-
tients received HCTwith myeloablative Cy 120 mg/kg in 2 days and
IVBu 12,8 mg/m2 or OBu 16 mg/kg in 4 days.
Results: All patients grafted as follows: neutrophils. 0.5 x 109/l at
a median of 17 days and platelet. 20 x 109/l at 21 days. Fifteen pa-
tients (23%) showed acute GVHD grade III-IV, 17 (26%) chronic
GVHD, 15 (23%) liver dysfunction and 8 (12%) EVOH. There
were not differences in liver disease after HCT between two groups
(IVBu vs OBu) and also in incidence of infections and relapse. With
a median follow-up for alive patients of 54 months (15-120), 4-year
overall survival was 39% and 50% for OBu and IVBu, respectively (p
5 0.36) with no differences between the conditioning regimens
groups. 4-year progression-free survival was 81% and 54% for
OBu and IVBu, respectively (p 5 309).Relapse rate (28%) and non-related relapse toxicity (20%) do not
be higher than what we had observed with the standard regimen with
OBu (13% and 42% respectively).
Conclusions: Intravenous Busulfan is an effective drug in both reg-
imens for patients with acute leukemia. Mortality related to relapse
and toxicity do not appear to be higher than those observed with
oral Busulfan regimens.443
INCIDENCE AND CLINICAL FEATURES OF IDIOPATHIC PNEUMONIA SYN-
DROME AND DIFFUSE ALVEOLAR HEMORRHAGE AFTER UNRELATED
CORD BLOOD TRANSPLANTATION
Nishida, A.1, Wake, A.1, Yamamoto, H.1, Ishiwata, K.1, Nakano, N.1,
Tsuji, M.1, Asano-Mori, Y.1, Uchida, N.1, Izutsu, K.1, Araoka, H.2,
Yoneyama, A.2, Makino, S.3, Taniguchi, S.1 1Toranomon Hospital,
Tokyo, Japan; 2Toranomon Hospital, Tokyo, Japan; 3Toranomon
Hospital, Tokyo, Japan
Background: Idiopathic pneumonia syndrome (IPS) and diffuse al-
veolar hemorrhage (DAH) are non-infectious pulmonary complica-
tions of hematopoietic stem cell transplantation (HSCT) with
unclear pathogenesis and treatment.
Objective and method: To investigate the incidence and clinical
features of IPS/DAH after unrelated cord blood transplantation
(uCBT), we retrospectively analyzed 370 patients underwent
uCBT from January 2005 to June 2010 at ToranomonHospital. Di-
agnosis of IPS/DAH was made by multilobar infiltrates on CXR or
CT, clinical signs of pneumonia: cough, dyspnea, or rales, abnormal
physiology: increased arterial-alveolar oxygen gradient, or the need
for supplemental oxygen support, and no evidence of respiratory
tract infection.
Result: Twenty five cases of IPS/DAH were identified, with inci-
dence of 6.8%. The median-age was 59 years (range; 26-72). Nine-
teen patients underwent transplantation for leukemia, 4 for
malignant lymphoma, and 2 for aplastic anemia. IPS/DAHwas diag-
nosed at a median of 34 days (range; 8-93) after uCBT. All patients
were administered mPSL therapy. Nine of 25 patients were admin-
istered etanercept combined with mPSL pulse therapy. Five of 9 had
not responded, while 4 responders had worse their respiratory con-
dition after discontinuation of etanercept therapy. Twenty four of 25
died of respiratory failure.
Conclusion: IPS /DAH after uCBT are fetal pulmonary complica-
tions. It is suggested that the incidence of IPS/DAH after uCBT ap-
pears similar to that observed after transplantation using other
sources. But our results suggested that the existing treatment such
as etanercept combined mPSL pulse have only limited efficacy as
a therapy for IPS/DAH after uCBT. Further research is needed to
characterize the condition of this syndrome and to investigate the
optimal therapy and prophylaxis.
